Epidemiology, pathophysiology and contemporary management of cardiogenic shock–a position statement from the Heart Failure Association of the European Society …

O Chioncel, J Parissis, A Mebazaa… - European journal of …, 2020 - Wiley Online Library
Cardiogenic shock (CS) is a complex multifactorial clinical syndrome with extremely high
mortality, develo** as a continuum, and progressing from the initial insult (underlying …

Targeting the sarcomere in inherited cardiomyopathies

SJ Lehman, C Crocini, LA Leinwand - Nature Reviews Cardiology, 2022 - nature.com
Variants in> 12 genes encoding sarcomeric proteins can cause various cardiomyopathies.
The two most common are hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy …

Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use

Z Papp, P Agostoni, J Alvarez, D Bettex… - Journal of …, 2020 - journals.lww.com
Levosimendan was first approved for clinical use in 2000, when authorization was granted
by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely …

Treatments targeting inotropy: a position paper of the Committees on Translational Research and Acute Heart Failure of the Heart Failure Association of the European …

C Maack, T Eschenhagen, N Hamdani… - European heart …, 2019 - academic.oup.com
Acute heart failure (HF) and in particular, cardiogenic shock are associated with high
morbidity and mortality. A therapeutic dilemma is that the use of positive inotropic agents …

Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan

Z Papp, I Édes, S Fruhwald, SG De Hert… - International journal of …, 2012 - Elsevier
The molecular background of the Ca2+-sensitizing effect of levosimendan relates to its
specific interaction with the Ca2+-sensor troponin C molecule in the cardiac myofilaments …

Targeting the sarcomere to correct muscle function

PM Hwang, BD Sykes - Nature reviews Drug discovery, 2015 - nature.com
Various human diseases can disrupt the balance between muscle contraction and
relaxation. Sarcomeric modulators can be used to readjust this balance either indirectly by …

Structure and function of cardiac troponin C (TNNC1): Implications for heart failure, cardiomyopathies, and troponin modulating drugs

MX Li, PM Hwang - Gene, 2015 - Elsevier
In striated muscle, the protein troponin complex turns contraction on and off in a calcium-
dependent manner. The calcium-sensing component of the complex is troponin C, which is …

Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects

A Pathak, M Lebrin, A Vaccaro… - Journal of clinical …, 2013 - Wiley Online Library
What is known and objective Positive inotropic agents are frequently used in acute
decompensated heart failure (ADHF) due to left ventricular systolic dysfunction. These …

[PDF][PDF] Levosimendan, a new inotropic and vasodilator agent

WG Toller, C Stranz, DC Warltier - Anesthesiology, 2006 - jvsmedicscorner.com
This article has been selected for the Anesthesiology CME Program. After reading the
article, go to http://www. asahq. org/journal-cme to take the test and apply for Category 1 …

Evidence-based use of levosimendan in different clinical settings

L De Luca, WS Colucci, MS Nieminen… - European heart …, 2006 - academic.oup.com
Levosimendan is a new calcium sensitizer and K-ATP channel opener. Compared with other
inodilators, it improves myocardial contractility without increasing oxygen requirements and …